Earnings per share for the last twelve months: Caris Life Sciences Inc (CAI)

Corporate company logo of Caris (CAI)

Caris Life Sciences, Inc. (CAI) is shielded by internal demand but remains dependent on global reagent supplies. The aggressive development of liquid biopsy and AI-driven transcriptome analysis enhances its scientific potential, establishing a foundation for personalized therapy. The TTM annual earnings per share illustrates revenue dynamics, where 0.34 determines the current status of the parameter, confirming the synergy between biology and artificial intelligence.

Caris Life Sciences, Inc. (CAI) - Net earnings per one share for the last twelve months from 06/19/2025 to 11/18/2026

Metric breakdowns and analytics for Caris Corp (CAI)

- company stock exchange capitalization indicators:
Fundamental company analysis:Caris Life Sciences Inc (CAI)
Manufactured products of Caris

The operational efficiency of Caris Life Sciences (CAI) robotic laboratories is directly reflected in the trend of the rolling annual earnings per share. This indicator is calculated by dividing the total net income over the last four quarters by the total number of outstanding shares, allowing investors to objectively assess the real return on a single asset and determine the fair market capitalization level of the business.